New to Parola? Get 20% off on your first project

First vaccine to fully immunize against malaria builds on pandemic-driven RNA tech

September 23, 2021
Share on linkedin
Share on twitter
Share on facebook
First vaccine to fully immunize against malaria builds on pandemic-driven RNA tech

The article, “First vaccine to fully immunize against malaria builds on pandemic-driven RNA tech”, written by Monisha Ravisetti, was first published in The Academic Times. Parola Analytics provided technical research for this story.


Consistently ranked as one of the leading causes of death around the world, malaria doesn’t have an effective vaccine yet. But researchers have invented a promising new blueprint for one — with properties akin to the novel RNA-based vaccine for COVID-19.

Making a vaccine for malaria is challenging because its associated parasite, Plasmodium, contains a protein that inhibits production of memory T-cells, which protect against previously encountered pathogens. If the body can’t generate these cells, a vaccine is ineffective. But scientists recently tried a new approach using an RNA-based platform.

Their design circumvented the sneaky protein, allowed the body to produce the needed T-cells and completely immunized against malaria. The patent application for their novel vaccine, which hasn’t yet been tested on humans, was published by the U.S. Patent & Trademark Office on Feb. 4.

Read the full article

Authors: Academic Times

Subscribe to our newsletter

  • Questions? Check our privacy policy.
  • This field is for validation purposes and should be left unchanged.